Breast Cancer Clinical Trial
Aims: To evaluate the role of monoclonal antibodies in the detection of cancer specific
antigens in blood and tumor tissue, and the potential use of these antibodies for future
evaluation for therapy. Also, to evaluate the presence of circulating tumor cells (CTCs) and
to study EMT (epithelial-mesenchymal) signature changes during chemotherapy.
Methods: To take 20mls of blood from advanced breast cancer patients before a new course of
anti-cancer therapy, and another 20mls of blood 3 weeks after treatment. In addition,
Consent will be obtained to cut 10-15 tissue sections from their archival tumor specimens.
Whenever possible, the blood taking will be timed such that no additional needle prick will
be done specifically for the purpose of the study, by coinciding it with standard blood
taking which is required for the patient's treatment.
Importance of proposed research to science or medicine:Detection of tumor specific antigens
in the blood may potentially reduce the need for more invasive biopsies for confirmation of
diagnosis of cancer or follow-up of cancer in the future. The identification and development
of antibodies specific to these tumor antigens or markers may offer future therapeutic
options, or as a vehicle to deliver cytotoxic therapy. Identification of CTCs as well as
understanding the changes that occur in EMT signature in these circulating tumor cells may
serve as a means of potential means of prognostication and modification of therapy in the
future.
Potential Benefits and Risks: Potential risks to the patient include that of blood taking
(pain, feeling faint, infection). Patients will not benefit directly from the study but the
knowledge gained may help the management of future patients.
Cancer biomarkers, such as antigens and circulating tumor cells, may be a potential area to
developing new methods of diagnosis and treatment of cancer. Monoclonal antibiotics are now
able to be identified and isolated that may specifically target progenitors of breast cancer
as well as CTCs. The changes that occur to CTCs during treatment may serve as a means of
prognostication, as well as allow for therapeutic modifications. Clinical correlative
studies into these areas (MAbs and CTCs) will serve to determine the role of these in
clinical application in the future.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |